Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hepatitis

Free Subscription Articles published in Dig Dis Sci Retrieve available abstracts of 68 articles: HTML format

Single Articles

July 2024
1. MAKOVICH Z, Radosavljevic I, Chapyala S, Handley G, et al
   Rationale for Hepatitis C Virus Treatment During Hematopoietic Stem Cell Transplant in the Era of Novel Direct-Acting Antivirals.
   Dig Dis Sci. 2024 Jul 11. doi: 10.1007/s10620-024-08541.
   PubMed     Abstract available
   
   
   
2. CHANG CW, Hsu WF, Tseng KC, Chen CY, et al
   Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan.
   Dig Dis Sci. 2024 Jul 4. doi: 10.1007/s10620-024-08512.
   PubMed     Abstract available
   
   
   June 2024
3. LEY D, Lazarus S, Forati AM, Farraye FA, et al
   High Rates of Seroprotection to Hepatitis B After a Hepatitis B Challenge Dose in Previously Vaccinated Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy.
   Dig Dis Sci. 2024 Jun 21. doi: 10.1007/s10620-024-08527.
   PubMed     Abstract available
   
   
   
4. HEALEY MA, Ramalingam G, Hang Y, Smirnova E, et al
   Utility of Lille Score in Predicting 30-Day Survival in Steroid-Treated Alcohol-Associated Hepatitis.
   Dig Dis Sci. 2024 Jun 18. doi: 10.1007/s10620-024-08479.
   PubMed     Abstract available
   
   
   May 2024
5. PAN CW, Guifarro D, Poudel A, Abboud Y, et al
   Racial Disparities in Alcoholic Hepatitis Hospitalizations in the United States: Trends, Outcomes, and Future Projections.
   Dig Dis Sci. 2024 May 29. doi: 10.1007/s10620-024-08462.
   PubMed     Abstract available
   
   
   April 2024
6. LEE DU, Bhowmick K, Kolachana S, Schuster K, et al
   Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database.
   Dig Dis Sci. 2024 Apr 24. doi: 10.1007/s10620-024-08448.
   PubMed     Abstract available
   
   
   
7. CHANG ML, Le PH, Chen WT, Chen TD, et al
   Hepatic and Extrahepatic Characteristics of Autoimmune Hepatitis: A 23-year Hospital-Based Cohort Study.
   Dig Dis Sci. 2024 Apr 23. doi: 10.1007/s10620-024-08439.
   PubMed     Abstract available
   
   
   
8. PEARLMAN BL
   Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.
   Dig Dis Sci. 2024 Apr 5. doi: 10.1007/s10620-024-08393.
   PubMed     Abstract available
   
   
   February 2024
9. CON D, Tu S, Clayton-Chubb D, Lubel JS, et al
   Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
   Dig Dis Sci. 2024 Feb 20. doi: 10.1007/s10620-024-08354.
   PubMed     Abstract available
   
   
   
10. HUANG J, Cheng C, Li K, Zhu C, et al
    Effectiveness and Safety of Tenofovir Alafenamide Fumarate in the Prevention of Perinatal Hepatitis B Transmission: A Meta-Analysis.
    Dig Dis Sci. 2024 Feb 10. doi: 10.1007/s10620-023-08258.
    PubMed     Abstract available
    
    
    December 2023
11. POOLA S, Kratzer M, Sewell K, Tillmann HL, et al
    Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy.
    Dig Dis Sci. 2023;68:4511-4520.
    PubMed     Abstract available
    
    
    November 2023
12. SUN Y, Lu M, Feldman R, Saul M, et al
    Positive Predictive Value of Cirrhosis and Chronic Pancreatitis Diagnoses in Individuals with Alcohol Use Disorder: A Single-Center Study.
    Dig Dis Sci. 2023 Nov 29. doi: 10.1007/s10620-023-08183.
    PubMed     Abstract available
    
    
    October 2023
13. JINDAL A, Sharma MK, Vijayaraghavan R, Sm S, et al
    Severity of Acute Portal Hypertension Determines the Clinical Outcomes in Severe Alcoholic Hepatitis.
    Dig Dis Sci. 2023 Oct 31. doi: 10.1007/s10620-023-08144.
    PubMed     Abstract available
    
    
    
14. BUI HH, Nguyen ST, Phan ST, Nguyen KM, et al
    Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B.
    Dig Dis Sci. 2023 Oct 20. doi: 10.1007/s10620-023-08143.
    PubMed     Abstract available
    
    
    
15. KILANI Y, Arshad I, Aldiabat M, Bhatija RR, et al
    Autoimmune Hepatitis and Obstetrical Outcomes: A Nationwide Assessment.
    Dig Dis Sci. 2023 Oct 10. doi: 10.1007/s10620-023-08129.
    PubMed     Abstract available
    
    
    
16. EVON DM, Lin HS, Khalili M, Wahed AS, et al
    Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.
    Dig Dis Sci. 2023 Oct 7. doi: 10.1007/s10620-023-08108.
    PubMed     Abstract available
    
    
    September 2023
17. CZAJA AJ
    Introducing Molecular Chaperones into the Causality and Prospective Management of Autoimmune Hepatitis.
    Dig Dis Sci. 2023 Sep 27. doi: 10.1007/s10620-023-08118.
    PubMed     Abstract available
    
    
    August 2023
18. PAN C, Gish R, Jacobson IM, Hu KQ, et al
    Correction to: Diagnosis and Management of Hepatitis Delta Virus Infection.
    Dig Dis Sci. 2023 Aug 10. doi: 10.1007/s10620-023-08046.
    PubMed    
    
    
    July 2023
19. MOHAMED MF, Wadhavkar N, Elfanagely Y, Marino D, et al
    Etiologies and Outcomes of Transaminase Elevation > 1000 IU/L: A Systematic Review and Meta-Analysis.
    Dig Dis Sci. 2023;68:2843-2852.
    PubMed     Abstract available
    
    
    
20. HSU CL, Wang Y, Duan Y, Chu H, et al
    Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease.
    Dig Dis Sci. 2023;68:3059-3069.
    PubMed     Abstract available
    
    
    June 2023
21. PAN C, Gish R, Jacobson IM, Hu KQ, et al
    Diagnosis and Management of Hepatitis Delta Virus Infection.
    Dig Dis Sci. 2023 Jun 20. doi: 10.1007/s10620-023-07960.
    PubMed     Abstract available
    
    
    
22. KARIMI-SARI H, Falade-Nwulia O
    Hepatitis Delta Virus Infection in the United States: If You Seek, You May Find.
    Dig Dis Sci. 2023 Jun 14. doi: 10.1007/s10620-023-07961.
    PubMed    
    
    
    
23. MASOOD M, Siddique A, Kozarek RA
    Adult Hemophagocytic Lymphohistiocytosis Mimicking Acute Viral Hepatitis.
    Dig Dis Sci. 2023 Jun 8. doi: 10.1007/s10620-023-07985.
    PubMed     Abstract available
    
    
    May 2023
24. CZAJA AJ
    Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis.
    Dig Dis Sci. 2023 May 9. doi: 10.1007/s10620-023-07967.
    PubMed     Abstract available
    
    
    April 2023
25. RUSTAM LB, Vander Weg M, Chrischilles E, Tanaka T, et al
    Sociodemographic and Clinical Factors Associated with Nonattendance at the Hepatology Clinic.
    Dig Dis Sci. 2023 Apr 27. doi: 10.1007/s10620-023-07951.
    PubMed     Abstract available
    
    
    
26. WANG CL, Huang CH, Wu VC, Wu CL, et al
    Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C.
    Dig Dis Sci. 2023 Apr 18. doi: 10.1007/s10620-023-07943.
    PubMed     Abstract available
    
    
    
27. MAJEED NA, Alawad AS, Liem KS, Takyar V, et al
    Low Rate of Hepatitis B Reactivation Among Patients with Chronic Hepatitis C During Direct Acting Antiviral Therapy.
    Dig Dis Sci. 2023 Apr 6. doi: 10.1007/s10620-023-07916.
    PubMed     Abstract available
    
    
    February 2023
28. BONKOVSKY HL, Rudnick SP, Ma CD, Overbey JR, et al
    Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.
    Dig Dis Sci. 2023 Feb 22. doi: 10.1007/s10620-023-07859.
    PubMed     Abstract available
    
    
    
29. MA GX, Zhu L, Tan Y, Zhai S, et al
    A Comparative Trial of Improving Care for Underserved Asian Americans Infected with Hepatitis B Virus.
    Dig Dis Sci. 2023 Feb 7. doi: 10.1007/s10620-023-07840.
    PubMed     Abstract available
    
    
    
30. MATEOS-MUNOZ B, Buti M, Vazquez IF, Conde MH, et al
    Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
    Dig Dis Sci. 2023 Feb 3. doi: 10.1007/s10620-022-07817.
    PubMed     Abstract available
    
    
    
31. CHIU SM, Chang KC, Hu TH, Hung CH, et al
    Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
    Dig Dis Sci. 2023;68:665-675.
    PubMed     Abstract available
    
    
    December 2022
32. XU J, Wang Y, Feng H, Liu F, et al
    HBV/HCV Infection Was Not Significantly Independently Associated with COVID-19 Severity: A Meta-Analysis of Confounding Variables-Adjusted Data.
    Dig Dis Sci. 2022 Dec 23:1-3. doi: 10.1007/s10620-022-07799.
    PubMed    
    
    
    
33. JINDAL A, Agarwal S, Sharma S, Kumar M, et al
    Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
    Dig Dis Sci. 2022 Dec 23. doi: 10.1007/s10620-022-07778.
    PubMed     Abstract available
    
    
    
34. TAHATA Y, Sakamori R, Yamada R, Kodama T, et al
    Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.
    Dig Dis Sci. 2022 Dec 16. doi: 10.1007/s10620-022-07629.
    PubMed     Abstract available
    
    
    October 2022
35. CZAJA AJ
    Missing Causality and Heritability of Autoimmune Hepatitis.
    Dig Dis Sci. 2022 Oct 19. pii: 10.1007/s10620-022-07728.
    PubMed     Abstract available
    
    
    
36. LIU YC, Cheng YT, Chen YC, Hsieh YC, et al
    Correction: Comparing Predictability of Noninvasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.
    Dig Dis Sci. 2022 Oct 17. pii: 10.1007/s10620-022-07683.
    PubMed    
    
    
    
37. LIU CH, Jiang W, Wu DB, Zeng QM, et al
    Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection.
    Dig Dis Sci. 2022 Oct 13. pii: 10.1007/s10620-022-07695.
    PubMed     Abstract available
    
    
    September 2022
38. HONMA Y, Shibata M, Morino K, Koya Y, et al
    Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
    Dig Dis Sci. 2022 Sep 14. pii: 10.1007/s10620-022-07686.
    PubMed     Abstract available
    
    
    
39. YU Y, Li X, Wan T
    Effects of Hepatitis B Virus Infection on Patients with COVID-19: A Meta-Analysis.
    Dig Dis Sci. 2022 Sep 9. pii: 10.1007/s10620-022-07687.
    PubMed     Abstract available
    
    
    July 2022
40. LIU YC, Cheng YT, Chen YC, Hsieh YC, et al
    Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients Characters: 102 (< 120).
    Dig Dis Sci. 2022 Jul 27. pii: 10.1007/s10620-022-07621.
    PubMed     Abstract available
    
    
    
41. YARRA P, Dunn W, Younossi Z, Kuo YF, et al
    Association of Previous Gastric Bypass Surgery and Patient Outcomes in Alcohol-Associated Cirrhosis Hospitalizations.
    Dig Dis Sci. 2022 Jul 4. pii: 10.1007/s10620-022-07591.
    PubMed     Abstract available
    
    
    
42. FANG HW, Yen YH, Hung CH, Wang JH, et al
    Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
    Dig Dis Sci. 2022;67:3402-3411.
    PubMed     Abstract available
    
    
    June 2022
43. BERNSTEIN DE, Trinh HN, Schiff ER, Smith CI, et al
    Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV.
    Dig Dis Sci. 2022;67:2637-2645.
    PubMed     Abstract available
    
    
    May 2022
44. LLOYD C, Leighton J, Wong LL, Goulding A, et al
    Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma.
    Dig Dis Sci. 2022 May 17. pii: 10.1007/s10620-022-07525.
    PubMed     Abstract available
    
    
    
45. CLARK PJ, Valery PC, Strasser SI, Weltman M, et al
    Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
    Dig Dis Sci. 2022 May 13. pii: 10.1007/s10620-022-07483.
    PubMed     Abstract available
    
    
    
46. RAO A, Rule JA, Cerro-Chiang G, Stravitz RT, et al
    Role of Hepatitis C Infection in Acute Liver Injury/Acute Liver Failure in North America.
    Dig Dis Sci. 2022 May 11. pii: 10.1007/s10620-022-07524.
    PubMed     Abstract available
    
    
    
47. SHROFF H, Fix OK
    Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: Real or Imagined?
    Dig Dis Sci. 2022 May 9. pii: 10.1007/s10620-022-07509.
    PubMed    
    
    
    April 2022
48. CHOW KW, Pham NV, Ibrahim BM, Hong K, et al
    Autoimmune Hepatitis-Like Syndrome Following COVID-19 Vaccination: A Systematic Review of the Literature.
    Dig Dis Sci. 2022 Apr 29. pii: 10.1007/s10620-022-07504.
    PubMed     Abstract available
    
    
    
49. JONES E, Watkins M, Anderson E, Gelow K, et al
    Overlooked Symptoms in Autoimmune Hepatitis Negatively Impact Many Facets of Life.
    Dig Dis Sci. 2022 Apr 19. pii: 10.1007/s10620-022-07484.
    PubMed     Abstract available
    
    
    March 2022
50. ANIEMEKA C, Pillai AA
    HCC Mortality Trends-In with ALD (and NAFLD) and Out with HCV.
    Dig Dis Sci. 2022 Mar 14. pii: 10.1007/s10620-022-07434.
    PubMed    
    
    
    
51. RAMANI A, Tapper EB, Griffin C, Shankar N, et al
    Hepatocellular Carcinoma-Related Mortality in the USA, 1999-2018.
    Dig Dis Sci. 2022 Mar 14. pii: 10.1007/s10620-022-07433.
    PubMed     Abstract available
    
    
    
52. MAK LY, Wong DK, Cheung KS, Hui RW, et al
    Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.
    Dig Dis Sci. 2022 Mar 8. pii: 10.1007/s10620-022-07429.
    PubMed     Abstract available
    
    
    
53. SAAB S, Pham N, Wu W, Dang L, et al
    Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naive Chronic Hepatitis B Patients.
    Dig Dis Sci. 2022 Mar 4. pii: 10.1007/s10620-022-07402.
    PubMed     Abstract available
    
    
    February 2022
54. CZAJA AJ
    Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.
    Dig Dis Sci. 2022 Feb 11. pii: 10.1007/s10620-021-07378.
    PubMed     Abstract available
    
    
    January 2022
55. PANCHAL SA, Kaplan DE, Goldberg DS, Mahmud N, et al
    Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis.
    Dig Dis Sci. 2022 Jan 13. pii: 10.1007/s10620-021-07321.
    PubMed     Abstract available
    
    
    November 2021
56. CHANG JI, Sinn DH, Cho H, Kim S, et al
    Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
    Dig Dis Sci. 2021 Nov 20. pii: 10.1007/s10620-021-07312.
    PubMed     Abstract available
    
    
    September 2021
57. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B.
    Dig Dis Sci. 2021 Sep 2. pii: 10.1007/s10620-021-07157.
    PubMed     Abstract available
    
    
    July 2021
58. VAZ K, Little R, Majeed A, Kemp W, et al
    Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis.
    Dig Dis Sci. 2021 Jul 6. pii: 10.1007/s10620-021-07140.
    PubMed     Abstract available
    
    
    
59. TOKA B, Koksal AS, Eminler AT, Tozlu M, et al
    Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.
    Dig Dis Sci. 2021;66:2417-2426.
    PubMed     Abstract available
    
    
    June 2021
60. GELOW K, Chalasani S, Green K, Lammert C, et al
    Utilization and Impact of Complementary and Alternative Medicines in Symptomatic Autoimmune Hepatitis Patients.
    Dig Dis Sci. 2021 Jun 23. pii: 10.1007/s10620-021-07112.
    PubMed     Abstract available
    
    
    May 2021
61. CHEN J, Hubbard A, Bagley L, Shiau R, et al
    Prevalence of Latent Tuberculosis Infection Among Persons with Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis.
    Dig Dis Sci. 2021 May 30. pii: 10.1007/s10620-021-07056.
    PubMed     Abstract available
    
    
    
62. PINYOPORNPANISH K, Al-Yaman W, Dasarathy S, Romero-Marrero C, et al
    Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival.
    Dig Dis Sci. 2021 May 23. pii: 10.1007/s10620-021-07048.
    PubMed     Abstract available
    
    
    
63. LIN MH, Li HQ, Zhu L, Su HY, et al
    Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis.
    Dig Dis Sci. 2021 May 18. pii: 10.1007/s10620-021-07009.
    PubMed     Abstract available
    
    
    
64. HE WQ, Matthews GV, Liu B
    Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults.
    Dig Dis Sci. 2021 May 4. pii: 10.1007/s10620-021-07008.
    PubMed     Abstract available
    
    
    April 2021
65. LAMMERT C, Chalasani SN, Green K, Atkinson E, et al
    Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption.
    Dig Dis Sci. 2021 Apr 30. pii: 10.1007/s10620-021-06989.
    PubMed     Abstract available
    
    
    
66. CZAJA AJ
    Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.
    Dig Dis Sci. 2021 Apr 9. pii: 10.1007/s10620-021-06968.
    PubMed     Abstract available
    
    
    
67. CHANG PE, Tan CK, Cheah CC, Li W, et al
    Validation of the Expanded Baveno-VI Criteria for Screening Gastroscopy in Asian Patients with Compensated Advanced Chronic Liver Disease.
    Dig Dis Sci. 2021;66:1343-1348.
    PubMed     Abstract available
    
    
    February 2021
68. STERLING RK, King WC, Khalili M, Kleiner DE, et al
    Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.
    Dig Dis Sci. 2021 Feb 8. pii: 10.1007/s10620-021-06860.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.